Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Seidman

Showing results (331-340 of 386) with videos related to

Pageof 39
Sort By:
Clinical Breast Cancer|August 14, 2010
Phase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancerAlison K Conlin, Andrew D Seidman, Ariadne Bach, et al.
Clinical Breast Cancer|July 9, 2013
Randomized phase II trial of weekly vs. every 2 weeks vs. every 3 weeks nanoparticle albumin-bound paclitaxel with bevacizumab as first-line chemotherapy for metastatic breast cancerAndrew D Seidman, Alison K Conlin, Ariadne Bach, et al.
Free Radical Biology & Medicine|March 26, 2003
Effect of SOD1 overexpression on age- and noise-related hearing lossDonald E Coling, Kenneth C Y Yu, David Somand, et al.
Human Pathology|August 7, 2004
Borderline ovarian tumors: diverse contemporary viewpoints on terminology and diagnostic criteria with illustrative imagesJeffrey D Seidman, Robert A Soslow, Russell Vang, et al.
Future Oncology (London, England)|May 11, 2019
ATTAIN: Phase III study of etirinotecan pegol versus treatment of physician's choice in patients with metastatic breast cancer and brain metastasesDebu Tripathy, Sara M Tolaney, Andrew D Seidman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 26, 2001
Doxorubicin followed by sequential paclitaxel and cyclophosphamide versus concurrent paclitaxel and cyclophosphamide: 5-year results of a phase II randomized trial of adjuvant dose-dense chemotherapy for women with node-positive breast carcinomaM N Fornier, A D Seidman, M Theodoulou, et al.
Cancer Investigation|October 6, 2005
Phosphorylated/activated HER2 as a marker of clinical resistance to single agent taxane chemotherapy for metastatic breast cancerShanu Modi, Michael P DiGiovanna, Zhao Lu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 26, 2004
Phase II study of celecoxib and trastuzumab in metastatic breast cancer patients who have progressed after prior trastuzumab-based treatmentsChau T Dang, Andrew J Dannenberg, Kotha Subbaramaiah, et al.
Molecular Cancer Therapeutics|April 14, 2005
Resveratrol-induced apoptotic death in human U251 glioma cellsHao Jiang, Lijie Zhang, Jarret Kuo, et al.
Archives of Pathology & Laboratory Medicine|February 26, 2021
Pathologist Concordance for Ovarian Carcinoma Subtype Classification and Identification of Relevant Histologic Features Using Microscope and Whole Slide ImagingMarios A Gavrielides, Brigitte M Ronnett, Russell Vang, et al.
Pageof 39

Showing results (331-340 of 386) with videos related to

Sort By:
Pageof 39
Clinical Breast Cancer|August 14, 2010
Phase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancerAlison K Conlin, Andrew D Seidman, Ariadne Bach, et al.
Clinical Breast Cancer|July 9, 2013
Randomized phase II trial of weekly vs. every 2 weeks vs. every 3 weeks nanoparticle albumin-bound paclitaxel with bevacizumab as first-line chemotherapy for metastatic breast cancerAndrew D Seidman, Alison K Conlin, Ariadne Bach, et al.
Free Radical Biology & Medicine|March 26, 2003
Effect of SOD1 overexpression on age- and noise-related hearing lossDonald E Coling, Kenneth C Y Yu, David Somand, et al.
Human Pathology|August 7, 2004
Borderline ovarian tumors: diverse contemporary viewpoints on terminology and diagnostic criteria with illustrative imagesJeffrey D Seidman, Robert A Soslow, Russell Vang, et al.
Future Oncology (London, England)|May 11, 2019
ATTAIN: Phase III study of etirinotecan pegol versus treatment of physician's choice in patients with metastatic breast cancer and brain metastasesDebu Tripathy, Sara M Tolaney, Andrew D Seidman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 26, 2001
Doxorubicin followed by sequential paclitaxel and cyclophosphamide versus concurrent paclitaxel and cyclophosphamide: 5-year results of a phase II randomized trial of adjuvant dose-dense chemotherapy for women with node-positive breast carcinomaM N Fornier, A D Seidman, M Theodoulou, et al.
Cancer Investigation|October 6, 2005
Phosphorylated/activated HER2 as a marker of clinical resistance to single agent taxane chemotherapy for metastatic breast cancerShanu Modi, Michael P DiGiovanna, Zhao Lu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 26, 2004
Phase II study of celecoxib and trastuzumab in metastatic breast cancer patients who have progressed after prior trastuzumab-based treatmentsChau T Dang, Andrew J Dannenberg, Kotha Subbaramaiah, et al.
Molecular Cancer Therapeutics|April 14, 2005
Resveratrol-induced apoptotic death in human U251 glioma cellsHao Jiang, Lijie Zhang, Jarret Kuo, et al.
Archives of Pathology & Laboratory Medicine|February 26, 2021
Pathologist Concordance for Ovarian Carcinoma Subtype Classification and Identification of Relevant Histologic Features Using Microscope and Whole Slide ImagingMarios A Gavrielides, Brigitte M Ronnett, Russell Vang, et al.
Pageof 39